CLINICAL TRIALS PROFILE FOR TAZEMETOSTAT HYDROBROMIDE
✉ Email this page to a colleague
All Clinical Trials for TAZEMETOSTAT HYDROBROMIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04557956 ↗ | Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment | Recruiting | National Cancer Institute (NCI) | Phase 1/Phase 2 | 2021-02-01 | This phase I/II trial investigates the best dose, possible benefits and/or side effects of tazemetostat in combination with dabrafenib and trametinib in treating patients with melanoma that has a specific mutation in the BRAF gene (BRAFV600) and that has spread to other places in the body (metastatic). Tazemetostat, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving tazemetostat in combination with dabrafenib and trametinib may stabilize BRAFV600 mutated melanoma. |
| NCT05353439 ↗ | Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer | Not yet recruiting | National Cancer Institute (NCI) | Phase 1 | 2022-06-03 | This phase I trial tests the safety, side effects, and best dose of tazemetostat in combination with topotecan and pembrolizumab in treating patients with small cell lung cancer that has come back after a period of treatment (recurrent). Tazemetostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tazemetostat in combination with topotecan and pembrolizumab may shrink or stabilize recurrent small cell lung cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TAZEMETOSTAT HYDROBROMIDE
Condition Name
| Condition Name for TAZEMETOSTAT HYDROBROMIDE | |
| Intervention | Trials |
| Metastatic Malignant Neoplasm in the Central Nervous System | 1 |
| Metastatic Melanoma | 1 |
| Pathologic Stage IV Cutaneous Melanoma AJCC v8 | 1 |
| Platinum-Resistant Lung Small Cell Carcinoma | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for TAZEMETOSTAT HYDROBROMIDE
Trials by Country
Clinical Trial Progress for TAZEMETOSTAT HYDROBROMIDE
Clinical Trial Phase
Clinical Trial Sponsors for TAZEMETOSTAT HYDROBROMIDE
Sponsor Name
